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Summary 
 
Y-receptors control energy homeostasis, but the role of Npy6 receptors (Npy6r) is largely 
unknown. Young Npy6r-deficient (Npy6r−/−) mice have reduced body weight, lean mass, and 
adiposity, while older and high-fat-fed Npy6r−/− mice have low lean mass with increased 
adiposity. Npy6r−/− mice showed reduced hypothalamic growth hormone releasing hormone 
(Ghrh) expression and serum insulin-like growth factor-1 (IGF-1) levels relative to WT. This is 
likely due to impaired vasoactive intestinal peptide (VIP) signaling in the suprachiasmatic 
nucleus (SCN), where we found Npy6r coexpressed in VIP neurons. Peripheral administration 
of pancreatic polypeptide (PP) increased Fos expression in the SCN, increased energy 
expenditure, and reduced food intake in WT, but not Npy6r−/−, mice. Moreover, intraperitoneal 
(i.p.) PP injection increased hypothalamic Ghrh mRNA expression and serum IGF-1 levels in 
WT, but not Npy6r−/−, mice, an effect blocked by intracerebroventricular (i.c.v.) Vasoactive 
Intestinal Peptide (VPAC) receptors antagonism. Thus, PP-initiated signaling through Npy6r 
in VIP neurons regulates the growth hormone axis and body composition. 
Introduction 
 
Hypothalamic circuitries are important in receiving and integrating information from other 
brain areas as well as the periphery to control appetite and energy homeostasis (Sainsbury 
et al., 2002a). Among the many systems involved that influence orexigenic and anorexigenic 
processes in the hypothalamus, the neuropeptide Y (NPY) system is unique in that its major 
neuronal component, NPY, stimulates appetite and reduces energy expenditure, whereas its 
other family members, peptide YY (PYY) and pancreatic polypeptide (PP), which are mainly 
produced by endocrine cells in the periphery in response to food intake, act in an opposing 
fashion as satiety factors (Nguyen et al., 2011 and Zhang et al., 2011). All three peptides are 
able to signal through a set of five known Y-receptors (Npy1r, Npy2r, Ppyr1, Npy5r, and 
Npy6r) for which they have different affinities ( Nguyen et al., 2011 and Zhang et al., 2011). It 
has now been well established through work with transgenic and knockout mouse models 
that Npy1r and Npy5r are mostly responsible for the appetite-stimulatory and energy-
expenditure-related aspects of NPY signaling in the hypothalamus ( Nguyen et al., 2012), 
whereas the Npy2r and Ppyr1 are more critical for mediating satiety and other related aspects 
( Lin et al., 2009, Sainsbury et al., 2002b, Shi et al., 2010 and Zhang et al., 2010). However, 
despite the large amount of work being dedicated to unraveling functions of the NPY system 
in the regulation of energy homeostasis, no information is available for the role of the Npy6r. 
 The Npy6r gene is less conserved than the other Y-receptors. It exists only as a 
truncated version in primate species, including humans ( Gregor et al., 1996, Matsumoto 
et al., 1996 and Rose et al., 1997), and it is absent from the rat genome (Burkhoff et al., 
1998). The human Npy6r gene is located on chromosome 5q31 ( Gregor et al., 1996) and 
contains a single-base deletion resulting in a frameshift mutation and an early stop codon ( 
Gregor et al., 1996, Matsumoto et al., 1996 and Rose et al., 1997). Interestingly, an 
alternative splice variant of the Npy1r has been discovered in the mouse leading to a 
truncated isoform of the protein similar to the human Npy6r ( Nakamura et al., 1995), 
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suggesting a potential for altered signaling capacity by Npy1r. Importantly, mRNA for the 
truncated Npy1r and the Npy6r is produced in considerable amounts, and in the case of the 
human Npy6r, mRNA is produced in the heart, skeletal muscle, gastrointestinal tissues, and 
adrenal glands as well as in the brain ( Burkhoff et al., 1998, Gregor et al., 
1996 and Matsumoto et al., 1996), raising questions as to its possible function. 
 In contrast to humans, primates, and rats, the Npy6r gene is present in a 
nontruncated form in mice and rabbits ( Burkhoff et al., 1998 and Matsumoto et al., 1996). In 
the mouse, Npy6r is expressed in the developing embryo, skeletal muscle, kidney, and testes 
( Burkhoff et al., 1998 and Gregor et al., 1996). More importantly, in situ hybridization 
confirmed Npy6r expression in the mouse hypothalamus ( Weinberg et al., 1996), suggesting 
a role for this receptor in the regulation of energy homeostasis. Controversy surrounds the 
pharmacological profile of the Npy6r, with some studies claiming an Npy1r-like profile ( 
Weinberg et al., 1996), others indicating a Ppyr1-like profile ( Gregor et al., 1996), and a 
further study describing a unique pharmacological profile of Npy6r distinct from all the other Y 
receptors ( Mullins et al., 2000). This lack of consistent results arising from previous in vitro 
studies makes it difficult to ascertain the true pharmacology and potential physiological role of 
Npy6r. 
 Considering that mice are frequently used to determine the functional role of 
individual Y receptors, as well as the possibility that manipulation of the NPY system could be 
used for the development of new therapeutics for the treatment of obesity, diabetes, and 
related disorders, it is important to evaluate the contribution of all Y-receptors to the 
regulation of energy homeostasis, including Npy6r in the mouse. Therefore, in this study we 
investigated the metabolic characteristics and hypothalamic circuits activated by Npy6r 
signaling using Npy6r knockout mice (Npy6r−/−). To gain further insights into the critical 
physiological functions of Npy6r in mice, we also used our Npy6r−/− mouse model to 
determine the physiological ligand for this Y-receptor in vivo. 
 
Results 
 
Npy6r−/− Mice Are Viable and Have Normal Fertility 
Npy6r gene deletion was achieved by inserting a lacZ-IRES-neoR selection cassette into the 
coding frame of the Npy6r gene, allowing for identification of normal sites of gene expression 
via X-gal staining for β-galactosidase ( Figure 1A). Npy6r−/− mice were identified by PCR 
(Figure 1B) and confirmed by RT-PCR in various tissues (Figure 1C). Utilizing the introduced 
lacZ gene, we investigated the expression pattern of Npy6r in a variety of peripheral tissues 
and throughout the brain (see Figures S1 and S2 online). Only a subset of neurons within the 
hypothalamic supracharismatic nucleus (SCN) showed staining for β-gal, with no staining in 
any other area of the brain or the peripheral tissues examined, except testes. This 
demonstrates that Npy6r signaling in the brain is restricted to the SCN.  
 Npy6r−/− mice are viable; however, they are smaller than their wild-type (WT) 
counterparts (Figure 1D). Breeding of heterozygous Npy6r+/− mice resulted in live offspring 
with a genotype frequency not different from the expected Mendelian ratio (Table S1). Since 
Npy6r are expressed in the testes, we investigated whether deletion of this receptor impacts 
on fertility. Homozygous Npy6r−/− breeding pairs produced litters of a similar size to litters 
from WT and heterozygous breeding pairs (Table S1). Additionally, the mortality rate and 
gender ratio of pups born from heterozygous and homozygous breeding pairs did not 
significantly differ from that of WT (Table S1), further suggesting that disruption of Npy6r 
expression does not have any impact upon reproductive fitness. 
 
Lack of Npy6r Signaling Leads to an Early Reduction in Body Weight, Reduced Lean Mass, 
and the Development of Late-Onset Obesity 
Npy6r−/− mice showed reduced body weights relative to WT mice from 6 to 23 weeks of age 
but were no longer different at 24 weeks of age (Figure 1E). Npy6r−/− mice showed markedly 
reduced lean body mass when analyzed by whole-body dual-energy X-ray absorptiometry 
(DXA) at 9, 15, 20, and 24 weeks of age (Figure 1F). Importantly, lean body mass as a 
percent of body weight was also lower in 20- and 24-week-old Npy6r−/− mice compared to WT 
mice (Figure 1G), suggesting a disproportionate reduction in lean mass in the knockouts. 
Deletion of Npy6r also led to a transient reduction in absolute fat mass at 15 weeks of age ( 
Figure 1F), but at 20 or 24 weeks of age, Npy6r−/− mice showed greater adiposity (Figures 1F 
and IG). Consistent with the DXA scan results, the absolute or relative weights of dissected 
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white adipose tissues depots from the inguinal (i), epididymal (e), retroperitoneal (r), and 
mesenteric (m) sites and the brown adipose tissue (b) were significantly reduced in the 
absence of Npy6r in 15-week-old mice ( Figures 1H and 1I). In contrast to this reduction in 
adiposity at an early age, the weights of dissected white and brown adipose tissue depots 
were markedly greater in 24-week-old Npy6r−/− mice (Figures 1J and 1K). 
 
 
 
Figure 1. Chow-Fed Npy6r–/– Mice Exhibit Reduced Body Weight, Lean Mass, and Late-Onset Obesity
(A) Generation of the Npy6r-deficient mice.
(B) Genotyping was performed using GS(E)/GS(TE) or Neo(T)/GS(TE) primer pairs to amplify WT or knockout (Npy6r!/!) alleles, respectively.
(legend continued on next page)
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normalized for lean body mass (Figure 2G). Associated with this,
Npy6r!/! mice exhibited significantly increased activity (Fig-
ure 2H). We further inquired if changes in resting metabolic
rate could also contribute to the observed increase in energy
expenditure in Npy6r!/! mice by analyzing the energy expendi-
ture corresponding to the hour of least activity and found no sig-
nificant difference (Figures S4A and S4B; Table S2). In addition,
we assessed resting metabolic rate by extrapolating regression
lines of energy expenditure to physical activity (Zhang et al.,
2010) and found that resting energy expenditure is not signifi-
cantly different between 14-week-old Npy6r!/! and WT mice
(Figures S4A and S4B; Table S2). These results indicate that
the absence of Npy6r signaling does not increase basal meta-
bolic rate, and that the increase in energy expenditure observed
in 14-week-old Npy6r!/! mice was most likely due to the
increase in physical activity.
In addition to increased energy expenditure, 14-week-old
Npy6r!/! mice demonstrated a significant elevation in respira-
tory exchange ratio (RER), indicative of a reduction in lipid utiliza-
tion for whole-body energy production (Figure 2I). While the
elevated RER in Npy6r!/! mice may reflect the reduced
adiposity in 15-week-old Npy6r!/! mice (Figures 1F and 1H),
an RER value greater than 1.0, as seen in Npy6r!/! mice be-
tween 22:00 and 02:00 hr (Figure 2I), is associated with de
novo lipogenesis (Schutz, 2004). Since an increase in RER has
been demonstrated to predict weight gain (Marra et al., 2004;
Seidell et al., 1992; Weinsier et al., 1995), these data are in line
with the development of a late-onset increase in adiposity in
Npy6r!/! mice.
Secondary to the age-induced increase in adiposity, 23-week-
old Npy6r!/!mice displayed a significant reduction in RER (Fig-
ure 2J), suggesting an increased preference for lipids as an
oxidative fuel source. Consistent with the increased energy
expenditure and physical activity seen in 14-week-old Npy6r!/!
mice, 23-week-old Npy6r!/! showed significant increases in
energy expenditure when normalized for lean mass (Figures 2K
and 2L), as well as an increase in physical activity during the light
phase (Figure 2M). Furthermore, resting energy expenditure was
significantly higher in Npy6r!/!mice at 23 weeks of age (Figures
S4C and S4D; Table S2). These data suggest that, in addition to
increased physical activity, an increase in basal metabolic rate is
an important contributor to the increased total energy expendi-
ture observed in 23-week-old Npy6r!/! mice.
Npy6r Signaling Is Critical for Maintaining Glucose
Homeostasis in Mice
Skeletal muscle is a major site of insulin-mediated glucose
disposal, a d a r duction in lean mass is associated with impair-
ment in glucose ho eostasis and insulin sensitivity (Dulloo,
2009). Since Npy6r!/! mice demonstrated a significant reduc-
tion in lean body mass, we suspected that glucose metabolism
might be impaired in these mice. Interestingly, 15-week-old
Npy6r!/! mice exhibited normoglycemia under fasted and
nonfasted conditions (Figure 3A). Despite this, Npy6r!/! mice
at 15 weeks of age exhibited reduced serum insulin concentra-
tions, significantly so in the nonfasted condition (Figure 3B), sug-
gesting improved insulin action on glucose clearance. Indeed, in
response to i.p. glucose administration, the area under the curve
for the glucose tolerance tests were significantly reduced in
15-week-old Npy6r!/! mice (Figures 3C and 3D) despite signifi-
cantly lower serum insulin concentrations (Figure 3E).
In contrast, while fasted and nonfasted blood glucose levels
were similar between 24-week-old Npy6r!/! and WT mice (Fig-
ure 3F), the heightened fat accumulation in Npy6r!/! mice of
this age is accompanied by a significant elevation in nonfasting
serum insulin concentrations (Figure 3G), suggesting decreased
insulin action in older Npy6r!/! mice. Consistent with this, we
found that insulin signaling in muscle and liver, as determined
by Akt phosphorylation, is reduced in 24-week-old Npy6r!/!
mice (Figures S5A and S5B). Despite this, Npy6r deficiency did
not result in deterioration in glucose tolerance, with blood
glucose and serum insulin levels in response to i.p. glucose injec-
tion being similar between 24-week-old Npy6r!/! and WT mice
(Figures 3H and 3I).
Npy6r–/– Mice Show Exacerbated Diet-Induced Obesity
We next assessed the effect of Npy6r deletion in mice on a high-
fat diet (HFD), which was introduced at 7 weeks of age and
continued for 16 weeks. Relative toWT,Npy6r!/!mice exhibited
significantly lower starting body weights (Figure 4A) but
displayed significantly greater relative body weight gain on the
HFD (Figure 4B). Importantly, after 8 weeks on the HFD (i.e.,
15 weeks of age) Npy6r!/! mice showed similar body weights
to age-matched WT controls (Figure 4A), showing that the
normalization of body weight in 24-week-old chow-fed Npy6r!/!
mice seen in Figure 1E was accelerated by the obesogenic diet.
Consistent with the effect of Npy6r deletion in mice on a
normal chow diet (Figures 1F and 1G), HFD-fed Npy6r!/! mice
displayed reduced lean body mass as determined by whole-
body DXA scans and when expressed as either absolute weight
or as a percent of body weight (Figures 4C and 4D). Npy6r!/!
mice also showed significantly higher adiposity at 7 and
14 weeks after the commencement of HFD feeding (Figures 4C
and 4D). This greater adiposity was confirmed by significantly
greater absolute and relative masses of dissected white and
brown adipose tissue depots in Npy6r!/! mice after 16 weeks
on the HFD (Figures 4E and 4F). These data show that, together
with the suppression of lean body mass, the impact of Npy6r
(C) Npy6r mRNA expression was determined in various tissues, including the hypothalamus, testes, and inguinal white adipose tissue (i), by RT-PCR using
GAPDH as a housekeeping gene.
(D) A representative photograph of 15-week-old WT and Npy6r!/! mice.
(E) Body weight in Npy6r!/! and WT mice was measured on a weekly basis.
(F and G) Body composition (lean and fat mass) was determined by DXA and normalized to body weight at indicated time points in Npy6r!/! and WT mice.
(H–K) Absolute and relative (as a percent of body weight) weights of white adipose tissues from the inguinal (i), epidydimal (e), mesenteric (m), and retroperitoneal
(r) sites, and intrascapular brown adipose tissue (b) depots were measured in 15- and 24-week-old Npy6r!/! and WT mice.
(L–N) (L) Liver weight and (M and N) liver morphology were determined by the quantity of oil red O staining from 15- and 24-week-old Npy6r!/! and WT mice.
(O and P) Representative oil red O-stained liver sections fromWT and Npy6r!/!mice. Data are means ±SEM of 5–13 mice per group. See also Figures S1 and S2
and Table S1.
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 Since obesity is associated with ectopic lipid deposition in various tissues including 
the liver, we investigated this in our Npy6r−/− mice. Interestingly, we found a significant 
increase in liver weight relative to body weight in Npy6r−/− mice at 15 weeks of age 
(Figure 1L). This was associated with a significantly greater amount of lipid in the livers of 
these mice (Figure 1M), as determined by oil red O staining (Figure 1O). Consistent with this, 
24-week-old Npy6r−/− mice also exhibited significantly higher hepatic lipid accumulation 
(Figures 1N and 1P). Since Npy6r−/− mice showed reduced adiposity at 15 weeks of age 
(Figures 1F, 1H, and 1I), this result suggests that ectopic fat accumulation in the liver 
precedes the development of age-induced fat accumulation in Npy6r−/− mice. 
 
Reduced Body Weight and Preferential Fat Accumulation in Npy6r−/− Mice Are Associated 
with Increased Cumulative Food Intake Relative to Body Weight 
To determine if the reduction in body weight and altered body composition in Npy6r−/− mice 
could be explained by changes in feeding behavior, we analyzed the food intake of Npy6r−/− 
and WT mice. Spontaneous food intake and spillage did not differ significantly between 
genotypes at 15 weeks of age (Figure 2A). However, Npy6r−/− mice exhibited a trend toward 
increased daily food intake at 24 weeks of age (Figure 2B). In spite of this, Npy6r−/− mice 
displayed significantly greater fecal output at 15, but not at 24, weeks of age (Figures S3A 
and S3B). Following a 24 hr fast at 13 weeks of age, food intake, spillage (Figure 2C), and 
fecal output (Figure S3C) were similar between Npy6r−/− and WT mice. Since food spillage 
was not significantly different between Npy6r−/− and WT mice, we also monitored food intake 
as the amount of food removed from the hopper over the entire period between 16 and 
22 weeks of age and found no significant difference in cumulative food consumption 
(Figure 2D). Importantly, however, these differences were statistically significant when 
normalized for body weight (Figure 2E), indicating that increased food intake may contribute 
to the increased adiposity and weight gain in older Npy6r−/− mice. 
 Indirect calorimetry on 14-week-old Npy6r−/− mice revealed a significant increase in 
energy expenditure compared to WT, either when expressed as absolute values (Figure 2F) 
or when normalized for lean body mass (Figure 2G). Associated with this, Npy6r−/− mice 
exhibited significantly increased activity (Figure 2H). We further inquired if changes in resting 
metabolic rate could also contribute to the observed increase in energy expenditure in 
Npy6r−/− mice by analyzing the energy expenditure corresponding to the hour of least activity 
and found no significant difference (Figures S4A and S4B; Table S2). In addition, we 
assessed resting metabolic rate by extrapolating regression lines of energy expenditure to 
physical activity (Zhang et al., 2010) and found that resting energy expenditure is not 
significantly different between 14-week-old Npy6r−/− and WT mice (Figures S4A and S4B; 
Table S2). These results indicate that the absence of Npy6r signaling does not increase basal 
metabolic rate, and that the increase in energy expenditure observed in 14-week-old Npy6r−/− 
mice was most likely due to the increase in physical activity. 
 In addition to increased energy expenditure, 14-week-old Npy6r−/− mice demonstrated 
a significant elevation in respiratory exchange ratio (RER), indicative of a reduction in lipid 
utilization for whole-body energy production (Figure 2I). While the elevated RER in Npy6r−/− 
mice may reflect the reduced adiposity in 15-week-old Npy6r−/− mice (Figures 1F and 1H), an 
RER value greater than 1.0, as seen in Npy6r−/− mice between 22:00 and 02:00 hr (Figure 2I), 
is associated with de novo lipogenesis (Schutz, 2004). Since an increase in RER has been 
demonstrated to predict weight gain ( Marra et al., 2004, Seidell et al., 1992 and Weinsier 
et al., 1995), these data are in line with the development of a late-onset increase in adiposity 
in Npy6r−/− mice. 
 Secondary to the age-induced increase in adiposity, 23-week-old Npy6r−/− mice 
displayed a significant reduction in RER (Figure 2J), suggesting an increased preference for 
lipids as an oxidative fuel source. Consistent with the increased energy expenditure and 
physical activity seen in 14-week-old Npy6r−/− mice, 23-week-old Npy6r−/− showed significant 
increases in energy expenditure when normalized for lean mass (Figures 2K and 2L), as well 
as an increase in physical activity during the light phase (Figure 2M). Furthermore, resting 
energy expenditure was significantly higher in Npy6r−/− mice at 23 weeks of age (Figures S4C 
and S4D; Table S2). These data suggest that, in addition to increased physical activity, an 
increase in basal metabolic rate is an important contributor to the increased total energy 
expenditure observed in 23-week-old Npy6r−/− mice. 	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deficiency in enhancing adiposity in mice is exacerbated by
the HFD.
Interestingly, the exacerbated body weight gain and adipose
tissue accumulation in Npy6r!/! mice on a HFD occurred in
the presence of transient hyperphagia. While food intake in ab-
solute weight did not differ significantly between genotypes at
3 weeks after the introduction of HFD (Figure 4G), Npy6r!/!
mice consumed significantly more HFD relative to their body
weights compared to WT controls at this time point (Figure 4H).
In contrast, food intake of Npy6r!/! mice was significantly
reduced after 13 weeks on the HFD (Figures 4G and 4H). Reflec-
tive of the changes in absolute food consumption (Figure 4G),
fecal output was significantly reduced after 10 but not 3 weeks
of high-fat feeding in Npy6r!/! mice (Figure S3D). In response
to a 24 hr fast, young Npy6r!/! mice exhibited no change in
food intake (Figures 4I and 4J) or fecal output (Figure S3E),
whereas older knockouts demonstrated a significant reduction
in fasting-induced food intake (Figures 4K and 4L) and fecal
output (Figure S3F). The transient increase in nonfasted food
intake relative to body weight seen at 3 weeks after the provi-
sion of HFD (Figure 4H) may contribute to the accelerated
body weight gain in HFD-fed Npy6r!/! mice. Additionally, since
Figure 2. Altered Food Intake and Energy Homeostasis in Npy6r-Deficient Mice
(A–C) Daily and 24 hr fasting-induced food intake and spillage were assessed in Npy6r!/! and WT mice at indicated time points.
(D and E) Cumulative food consumption from 16- to 22-week-old Npy6r!/! and WT mice were recorded and normalized to total body weight.
(F–M) Light and dark cycle energy expenditure (normalized to total lean mass), ambulatory activity, and respiratory exchange ratio (RER) were determined in
metabolic chambers during indirect calorimetry studies in 14- and 23-week-old Npy6r!/! and WT mice. Significant time and genotype interaction effects are
indicated by J. Data are means ±SEM of five to nine mice per group. See also Figures S3 and S4 and Table S2.
Figure 3. Impact of Npy6r Deletion on Glucose Homeostasis in Mice
(A and B) Fasted and nonfasted blood glucose and serum insulin levels in 15- and (F and G) 24-week-old Npy6r!/! andWTmice were determined. (C–E) Fifteen-
and (H and I) 24-week-old Npy6r!/! and WT mice were fasted, and glucose tolerance tests (1 mg/kg) were performed. Blood glucose and corresponding serum
insulin levels were assessed at indicated time points in these mice. Results are means ±SEM of 5–11 mice per group. See also Figure S5.
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Npy6r Signaling Is Critical for Maintaining Glucose Homeostasis in Mice 
Skeletal muscle is a major site of insulin-mediated glucose disposal, and a reduction in lean 
mass is associated with impairment in glucose homeostasis and insulin sensitivity (Dulloo, 
2009). Since Npy6r−/− mice demonstrated a significant reduction in lean body mass, we 
suspected that glucose metabolism might be impaired in these mice. Interestingly, 15-week-
old Npy6r−/− mice exhibited normoglycemia under fasted and nonfasted conditions 
(Figure 3A). Despite this, Npy6r−/− mice at 15 weeks of age exhibited reduced serum insulin 
concentrations, significantly so in the nonfasted condition (Figure 3B), suggesting improved 
insulin action on glucose clearance. Indeed, in response to i.p. glucose administration, the 
area under the curve for the glucose tolerance tests were significantly reduced in 15-week-old 
Npy6r−/− mice (Figures 3C and 3D) despite significantly lower serum insulin concentrations 
(Figure 3E). 
 In contrast, while fasted and nonfasted blood glucose levels were similar between 24-
week-old Npy6r−/− and WT mice (Figure 3F), the heightened fat accumulation in Npy6r−/− mice 
of this age is accompanied by a significant elevation in nonfasting serum insulin 
concentrations (Figure 3G), suggesting decreased insulin action in older Npy6r−/− mice. 
Consistent with this, we found that insulin signaling in muscle and liver, as determined by Akt 
phosphorylation, is reduced in 24-week-old Npy6r−/− mice (Figures S5A and S5B). Despite 
this, Npy6r deficiency did not result in deterioration in glucose tolerance, with blood glucose 
and serum insulin levels in response to i.p. glucose injection being similar between 24-week-
old Npy6r−/− and WT mice (Figures 3H and 3I). 
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and (H and I) 24-week-old Npy6r!/! and WT mice were fasted, and glucose tolerance tests (1 mg/kg) were performed. Blood glucose and corresponding serum
insulin levels were assessed at indicated time points in these mice. Results are means ±SEM of 5–11 mice per group. See also Figure S5.
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Npy6r−/− Mice Show Exacerbated Diet-Induced Obesity 
We next assessed the effect of Npy6r deletion in mice on a high-fat diet (HFD), which was 
introduced at 7 weeks of age and continued for 16 weeks. Relative to WT, Npy6r−/− mice 
exhibited significantly lower starting body weights (Figure 4A) but displayed significantly 
greater relative body weight gain on the HFD (Figure 4B). Importantly, after 8 weeks on the 
HFD (i.e., 15 weeks of age) Npy6r−/− mice showed similar body weights to age-matched WT 
controls (Figure 4A), showing that the normalization of body weight in 24-week-old chow-fed 
Npy6r−/− mice seen in Figure 1E was accelerated by the obesogenic diet. 
 
 
 
 
 
Figure 4. Mice Lacking Npy6r Showed Exacerbated Diet-Induced Obesity
(A and B) Seven-week-old Npy6r!/! and WT mice underwent high-fat feeding for 16 weeks, and body weight was monitored on a weekly basis.
(C and D) Body composition (lean and fat mass) was determined by DXA and subsequently normalized to body weight.
(E and F) Weight of white adipose tissues from the inguinal (i), epidydimal (e), mesenteric (m), and retroperitoneal (r) sites, and intrascapular brown adipose tissue
(b) depots in high-fat-fed Npy6r!/! and WT mice were measured and expressed as absolute weight or as a percentage of body weight.
(G and H) Daily food intake in high-fat-fed Npy6r!/! and WT mice was recorded.
(I–L) Mice were fasted for 24 hr, and fasting-induced food intake was determined at indicated time points. Food intake results were expressed in absolute terms or
as a percentage of body weight.
(legend continued on next page)
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nonfasted and fasting-induced food intake at the later time point
were significantly reduced, lack of Npy6r in mice may lead to
increased feeding efficacy and greater body weight gain seen
in HFD-fed Npy6r!/! mice.
Using indirect calorimetry we identified that after 14 weeks on
theHFD,Npy6r!/!mice did not exhibit any difference in absolute
energy expenditure (Figure 4M). When adjusted for the differ-
ence in lean body mass, however, energy expenditure was
significantly greater in HFD-fed Npy6r!/! mice (Figure 4N). This
increase in energy expendit re was more pronounced than
that seen in chow-fed Npy6r!/! mice at either the younger age
or the older age (Figures 2G and 2L). Unlike in chow-fed animals
(Figure 2H–2J and 2M), we did not detect any significant differ-
ences in physical activity (Figure 4O) or RER (Figure 4P) between
HFD-fed Npy6r!/! and WT mice. These results show that the
increase in body weight gain and fat accumulation in Npy6r!/!
mice on the HFD is not due to reduced metabolism.
Interestingly, after 12 weeks on the HFD, Npy6r!/! mice still
displayed normoglycemia (Figure 4Q) but showed elevated
serum insulin levels, significantly so in the nonfasted state (Fig-
ure 4R). However, when assessed for glucose tolerance,
Npy6r!/!mice on HFD displayed markedly higher blood glucose
(Figure 4S) and serum insulin levels (Figure 4T) in response to i.p.
glucose injection, signifying impaired glucose metabolism.
Taken together, our data demonstrate that deficiency in Npy6r
in mice exacerbates diet-induced obesity and promotes the
associated abnormalities in glucose homeostasis.
Npy6r–/– Mice Have Impaired Central VIP Signaling in
Association with Reduced Serum IGF-1 and Blunted
Corticosterone Rhythm
In order to identify the underlying mechanism that leads to the
altered metabolic phenotype of Npy6r deficiency, we focused
on areas of highest Npy6r expression. As shown in Figures 5A,
S1, and S2, the strongest expression of Npy6r was found in
the hypothalamic SCN, with expression also detected in the
testes. It is known that reduction in circulating testosterone
levels is strongly linked to reduced lean body mass (Sattler
et al., 2009) and obesity (Nettleship et al., 2007). However,
Npy6r!/! mice did not show reduced serum testosterone levels
(Figure S6A), suggesting that this is not a major contributor to the
observed phenotype.
In order to elucidate possible pathways by which Npy6r
signaling may regulate energy balance and body composition,
we determined the molecular identity of Npy6r-expressing neu-
rons in the SCN by utilizing the introduced lacZ gene into the
Npy6r gene coding region to visualize the expression pattern
of Npy6r by staining for b-gal. Immunostaining with antibodies
against a variety of neuropeptides known to be expressed in
the SCN (Reghunandanan et al., 1993) revealed vasoactive in-
testinal peptide (VIP) as colocalized with the Npy6r (Figures
S6B and S6C). To further confirm this colocalization, we per-
formed in situ hybridization for Vip mRNA on SCN sections pre-
viously stained for LacZ. As shown in Figures 5B and 5C, almost
all LacZ-positive neurons express VIP, shown in the overlaying
silver grains. In contrast, immunostaining using arginine vaso-
pressin (AVP) antibody did not show any overlap in expression
with Npy6r-positive neurons (Figures 5D and 5E).
PP Is the Endogenous High-Affinity Ligand for the Npy6r
in Mice
The SCN receives input from a variety of areas in the brain (Welsh
et al., 2010). Additionally, the SCN is accessible to factors
derived from the circulation (Welsh et al., 2010), including periph-
erally derived PP and PYY. To investigate which Y-receptor
ligand is the most effective transducer of Npy6r function in vivo,
(M–P) After 12 weeks of high-fat feeding, energy expenditure, ambulatory activity, and respiratory exchange ratio (RER) were determined.
(Q and R) Fasted and nonfasted blood glucose and serum insulin levels were determined.
(S and T) Mice were fasted for 6 hr and injected with glucose (1 mg/kg). Blood glucose and corresponding insulin levels at indicated time points were assessed.
Data are means ±SEM of nine males per group. See also Figure S3.
Figure 5. Npy6r Deficiency Is Associated with Reduced Vip
Expression in the SCN
(A) Representative photographs of coronal brains sections showing the
distribution of Npy6r as indicated by lacZ expression in the mouse SCN.
(B and C) Representative photographs showing coexpression of lacZ and Vip
mRNA in neurons of the SCN of Npy6r!/! mice.
(D and E) Representative photographs showing the absence of lacZ and
arginine vasopressin (AVP) colocalization in the suprachiasmatic nucleus
(SCN) of Npy6r!/! mice. Light green and dark blue arrows denote neurons
expressing only AVP and only lacZ, respectively. See also Figure S6.
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 Consistent with the effect of Npy6r deletion in mice on a normal chow diet ( Figures 
1F and 1G), HFD-fed Npy6r−/− mice displayed reduced lean body mass as determined by 
whole-body DXA scans and when expressed as either absolute weight or as a percent of 
body weight (Figures 4C and 4D). Npy6r−/− mice also showed significantly higher adiposity at 
7 and 14 weeks after the commencement of HFD feeding (Figures 4C and 4D). This greater 
adiposity was confirmed by significantly greater absolute and relative masses of dissected 
white and brown adipose tissue depots in Npy6r−/− mice after 16 weeks on the HFD (Figures 
4E and 4F). These data show that, together with the suppression of lean body mass, the 
impact of Npy6r deficiency in enhancing adiposity in mice is exacerbated by the HFD. 
 Interestingly, the exacerbated body weight gain and adipose tissue accumulation in 
Npy6r−/− mice on a HFD occurred in the presence of transient hyperphagia. While food intake 
in absolute weight did not differ significantly between genotypes at 3 weeks after the 
introduction of HFD (Figure 4G), Npy6r−/− mice consumed significantly more HFD relative to 
their body weights compared to WT controls at this time point (Figure 4H). In contrast, food 
intake of Npy6r−/− mice was significantly reduced after 13 weeks on the HFD (Figures 4G and 
4H). Reflective of the changes in absolute food consumption (Figure 4G), fecal output was 
significantly reduced after 10 but not 3 weeks of high-fat feeding in Npy6r−/− mice 
(Figure S3D). In response to a 24 hr fast, young Npy6r−/− mice exhibited no change in food 
intake (Figures 4I and 4J) or fecal output (Figure S3E), whereas older knockouts 
demonstrated a significant reduction in fasting-induced food intake (Figures 4K and 4L) and 
fecal output (Figure S3F). The transient increase in nonfasted food intake relative to body 
weight seen at 3 weeks after the provision of HFD (Figure 4H) may contribute to the 
accelerated body weight gain in HFD-fed Npy6r−/− mice. Additionally, since nonfasted and 
fasting-induced food intake at the later time point were significantly reduced, lack of Npy6r in 
mice may lead to increased feeding efficacy and greater body weight gain seen in HFD-fed 
Npy6r−/− mice. 
 Using indirect calorimetry we identified that after 14 weeks on the HFD, Npy6r−/− mice 
did not exhibit any difference in absolute energy expenditure (Figure 4M). When adjusted for 
the difference in lean body mass, however, energy expenditure was significantly greater in 
HFD-fed Npy6r−/− mice (Figure 4N). This increase in energy expenditure was more 
pronounced than that seen in chow-fed Npy6r−/− mice at either the younger age or the older 
age (Figures 2G and 2L). Unlike in chow-fed animals (Figure 2H–2J and 2M), we did not 
detect any significant differences in physical activity (Figure 4O) or RER (Figure 4P) between 
HFD-fed Npy6r−/− and WT mice. These results show that the increase in body weight gain and 
fat accumulation in Npy6r−/− mice on the HFD is not due to reduced metabolism. 
 Interestingly, after 12 weeks on the HFD, Npy6r−/− mice still displayed normoglycemia 
(Figure 4Q) but showed elevated serum insulin levels, significantly so in the nonfasted state 
(Figure 4R). However, when assessed for glucose tolerance, Npy6r−/− mice on HFD displayed 
markedly higher blood glucose (Figure 4S) and serum insulin levels (Figure 4T) in response 
to i.p. glucose injection, signifying impaired glucose metabolism. Taken together, our data 
demonstrate that deficiency in Npy6r in mice exacerbates diet-induced obesity and promotes 
the associated abnormalities in glucose homeostasis. 
 
Npy6r−/− Mice Have Impaired Central VIP Signaling in Association with Reduced Serum IGF-1 
and Blunted Corticosterone Rhythm 
In order to identify the underlying mechanism that leads to the altered metabolic phenotype of 
Npy6r deficiency, we focused on areas of highest Npy6r expression. As shown in Figures 5A, 
S1, and S2, the strongest expression of Npy6r was found in the hypothalamic SCN, with 
expression also detected in the testes. It is known that reduction in circulating testosterone 
levels is strongly linked to reduced lean body mass ( Sattler et al., 2009) and obesity 
(Nettleship et al., 2007). However, Npy6r−/− mice did not show reduced serum testosterone 
levels (Figure S6A), suggesting that this is not a major contributor to the observed phenotype. 
 In order to elucidate possible pathways by which Npy6r signaling may regulate 
energy balance and body composition, we determined the molecular identity of Npy6r-
expressing neurons in the SCN by utilizing the introduced lacZ gene into the Npy6r gene 
coding region to visualize the expression pattern of Npy6r by staining for β-gal. 
Immunostaining with antibodies against a variety of neuropeptides known to be expressed in 
the SCN ( Reghunandanan et al., 1993) revealed vasoactive intestinal peptide (VIP) as 
colocalized with the Npy6r ( Figures S6B and S6C). To further confirm this colocalization, we 
performed in situ hybridization for Vip mRNA on SCN sections previously stained for LacZ. As 
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shown in Figures 5B and 5C, almost all LacZ-positive neurons express VIP, shown in the 
overlaying silver grains. In contrast, immunostaining using arginine vasopressin (AVP) 
antibody did not show any overlap in expression with Npy6r-positive neurons ( Figures 5D 
and 5E). 
 
 
 
PP Is the Endogenous High-Affinity Ligand for the Npy6r in Mice 
The SCN receives input from a variety of areas in the brain (Welsh et al., 2010). Additionally, 
the SCN is accessible to factors derived from the circulation (Welsh et al., 2010), including 
peripherally derived PP and PYY. To investigate which Y-receptor ligand is the most effective 
transducer of Npy6r function in vivo, we examined the expression of Fos in the SCN of 
Npy6r−/− and WT mice in response to i.p. administration of either PP, PYY, PYY3-36, or 
saline. Injection of PYY or PYY3-36 into WT mice did not induce any significant differences in 
Fos expression in the SCN compared to saline controls (Figure 6A) but significantly increased 
Fos expression in other areas like the arcuate nucleus (ARC) (data not shown). Importantly, a 
significant increase in Fos immunoreactivity in the SCN of WT mice was seen following i.p. 
PP injection, and this effect was absent in Npy6r−/− mice (Figures 6A and 6B). To further 
nonfasted and fasting-induced food intake at the later time point
were significantly reduced, lack of Npy6r in mice may lead to
increased feeding efficacy and greater body weight gain seen
in HFD-fed Npy6r!/! mice.
Using indirect calorimetry we identified that after 14 weeks on
theHFD,Npy6r!/!mice did not exhibit any difference in absolute
energy expenditure (Figure 4M). When adjusted for the differ-
ence in lean body mass, however, energy expenditure was
significantly greater in HFD-fed Npy6r!/! mice (Figure 4N). This
increase in energy expenditure was more pronounced than
that seen in chow-fed Npy6r!/! mice at either the younger age
or the older age (Figures 2G and 2L). Unlike in chow-fed animals
(Figure 2H–2J and 2M), we did not detect any significant differ-
ences in physical activity (Figure 4O) or RER (Figure 4P) between
HFD-fed Npy6r!/! and WT mice. These results show that the
increase in body weight gain and fat accumulation in Npy6r!/!
mice on the HFD is not due to reduced metabolism.
Interestingly, after 12 weeks on the HFD, Npy6r!/! mice still
displayed normoglycemia (Figure 4Q) but showed elevated
serum insulin levels, significantly so in the nonfasted state (Fig-
ure 4R). However, when assessed for glucose tolerance,
Npy6r!/!mice on HFD displayed markedly higher blood glucose
(Figure 4S) and serum insulin levels (Figure 4T) in response to i.p.
glucose injection, signifying impaired glucose metabolism.
Taken together, our data demonstrate that deficiency in Npy6r
in mice exacerbates diet-induced obesity and promotes the
associated abnormalities in glucose homeostasis.
Npy6r–/– Mice Have Impaired Central VIP Signaling in
Association with Reduced Serum IGF-1 and Blunted
Corticosterone Rhythm
In order to identify the underlying mechanism that leads to the
altered metabolic phenotype of Npy6r deficiency, we focused
on areas of highest Npy6r expression. As shown in Figures 5A,
S1, and S2, the strongest expression of Npy6r was found in
the hypothalamic SCN, with expression also detected in the
testes. It is known that reduction in circulating testosterone
levels is strongly linked to reduced lean body mass (Sattler
et al., 2009) and obesity (Nettleship et al., 2007). However,
Npy6r!/! mice did not show reduced serum testosterone levels
(Figure S6A), suggesting that this is not a major contributor to the
observed phenotype.
In order to elucidate possible pathways by which Npy6r
signaling may regulate energy balance and body composition,
we determined the molecular identity of Npy6r-expressing neu-
rons in the SCN by utilizing the introduced lacZ gene into the
Npy6r gene coding region to visualize the expression pattern
of Npy6r by staining for b-gal. Immunostaining with antibodies
against a variety of neuropeptides known to be expressed in
the SCN (Reghunandanan et al., 1993) revealed vasoactive in-
testinal peptide (VIP) as colocalized with the Npy6r (Figures
S6B and S6C). To further confirm this colocalization, we per-
formed in situ hybridization for Vip mRNA on SCN sections pre-
viously stained for LacZ. As shown in Figures 5B and 5C, almost
all LacZ-positive neurons express VIP, shown in the overlaying
silver grains. In contrast, immunostaining using arginine vaso-
pressin (AVP) antibody did not show any overlap in expression
with Npy6r-positive neurons (Figures 5D and 5E).
PP Is the Endogenous High-Affinity Ligand for the Npy6r
in Mice
The SCN receives input from a variety of areas in the brain (Welsh
et al., 2010). Additionally, the SCN is accessible to factors
derived from the circulation (Welsh et al., 2010), including periph-
erally derived PP and PYY. To investigate which Y-receptor
ligand is the most effective transducer of Npy6r function in vivo,
(M–P) After 12 weeks of high-fat feeding, energy expenditure, ambulatory activity, and respiratory exchange ratio (RER) were determined.
(Q and R) Fasted and nonfasted blood glucose and serum insulin levels were determined.
(S and T) Mice were fasted for 6 hr and injected with glucose (1 mg/kg). Blood glucose and corresponding insulin levels at indicated time points were assessed.
Data are means ±SEM of nine males per group. See also Figure S3.
Figure 5. Npy6r Deficiency Is Associated with Reduced Vip
Expression in the SCN
(A) Representative photographs of coronal brains sections showing the
distribution of Npy6r as indicated by lacZ expression in the mouse SCN.
(B and C) Representative photographs showing coexpression of lacZ and Vip
mRNA in neurons of the SCN of Npy6r!/! mice.
(D and E) Representative photographs showing the absence of lacZ and
arginine vasopressin (AVP) colocalization in the suprachiasmatic nucleus
(SCN) of Npy6r!/! mice. Light green and dark blue arrows denote neurons
expressing only AVP and only lacZ, respectively. See also Figure S6.
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confirm this, we performed radioligand-binding assays on brain sections from WT and 
Npy6r−/− mice using I125-labeled PP. Supporting the notion that PP is a physiological activator 
of Npy6r, I125-labeled PP binding was detected in the SCN of WT mice, but not in Npy6r−/− 
brain sections (Figure S7A). By contrast, the binding of I125-labeled PP was not observed in 
WT brain slices cotreated with human PP (Figure S7A). This raises the possibility that 
increases in circulating PP levels due to food intake or hypoglycemia can trigger Npy6r-
mediated events in the SCN. 
 
  
 
Figure 6. Pancreatic Polypeptide Is the Endogenous Ligand for the Npy6r In Vivo
(A and B)WT andNpy6r!/!mice were injectedwith either saline, PP (200 mg/kg), PYY (200 mg/kg), or PYY 3-36 (200 mg/kg). Fos expression in the suprachiasmatic
nucleus (SCN) of the hypothalamus was assessed by immunohistochemistry after 30 min injection. Fos-positive neurons in SCN brain sections were quantified.
(C) WT and Npy6r!/! mice were injected with either saline or PP, and PFA perfused brains were extracted and processed for immunohistochemistry with
antibodies to p-ERK.
(D and E)WT andNpy6r!/!mice were injectedwith either saline or PP (300 mg/kg) as indicated, and oxygen consumption and energy expenditure weremonitored
by indirect calorimetry.
(F and G) WT and Npy6r!/! mice were fasted for 24 hr, and prior to food being given mice were injected with either saline or PP (300 mg/kg) as indicated.
Fasting-induced food intake was determined for a period of 24 hr. Data are means ±SEM of three to six mice per group. See also Figure S7.
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 Previous studies have shown that extracellular signal-related kinase (ERK) is 
involved in mediating downstream signaling of Y receptors, including the Npy1r ( Shi et al., 
2013). To investigate whether ERK may also act as a downstream substrate for the Npy6r in 
response to PP, we injected WT and Npy6r−/− mice with either saline or PP and assessed 
ERK phosphorylation (p-ERK) by immunohistochemistry. While PP-induced p-ERK in the 
SCN region was elevated in WT mice compared to saline-injected controls, induction of pERK 
was strongly reduced in the SCN of Npy6r−/− mice in response to PP (Figure 6C). Taken 
together, these results are in keeping with the notion that PP is a physiological ligand for 
Npy6r and that ERK is an important downstream substrate for Npy6r signaling. 
 Strong evidence exists that PP regulates energy homeostasis by decreasing food 
intake and increasing energy expenditure via action on Ppyr1 ( Lin et al., 2009). Our findings 
that PP also activates the Npy6r raised the possibility that PP could regulate energy balance 
and appetite separately via an Npy6r signaling pathway. To examine this directly, both WT 
and Npy6r−/− mice were given an i.p. injection of saline or PP at 7 a.m. and 7 p.m., with 
subsequent monitoring of oxygen consumption, energy expenditure, and fasting-induced food 
intake. Consistent with previous studies, we found that oxygen consumption and energy 
expenditure were significantly increased in WT mice in response to PP injection (Figures 6D 
and 6E). However, these differences were not noted in Npy6r−/− mice (Figures 6D and 6E), 
indicating that Npy6r is required to mediate the effects of PP in the regulation of energy 
expenditure. In response to PP, both WT and Npy6r−/− mice exhibited reductions in fasting-
induced food intake compared to the corresponding saline group, significantly so in WT 
animals (Figures 6F and 6G). However, the degree to which PP suppressed food intake was 
significantly less in Npy6r−/− mice at an early time point (0–4 hr), and these differences were 
even greater when normalized for body weight (Figures 6F and 6G). 
 
PP-Mediated Npy6r Signaling Controls Vip Expression in the SCN 
Having established that Npy6r are coexpressed with VIP in neurons of the SCN, we 
hypothesized that the metabolic phenotype of Npy6r−/− mice may be explained by impairment 
in downstream actions of VIP. We determined Vip mRNA levels in the hypothalamus of WT 
and Npy6r−/− mice by quantitative real-time PCR. Consistent with our hypothesis of impaired 
VIP signaling, we found that Vip expression was significantly reduced in the hypothalamus of 
Npy6r−/− (Figure 7A), but not in other peripheral tissues such as colon, small intestine, or 
pancreas (Figure S7B). Lack of change in peripheral Vip mRNA levels is consistent with 
unaltered serum VIP levels in Npy6r−/− mice (Figure S7C). Additionally, Vip expression levels 
in the SCN of Npy6r−/− were significantly reduced as determined by in situ hybridization 
(Figures 7B and 7C), confirming that VIP signaling is disrupted in the SCN of Npy6r−/− mice. 
      VIP is known as a key regulator of the growth hormone (GH) axis (Asnicar et al., 
2002 and Niewiadomski et al., 2008), circadian rhythm (Aton et al., 2005, Brown et al., 2007, 
Pantazopoulos et al., 2010 and Piggins and Cutler, 2003), and glucocorticoid secretion (Loh 
et al., 2008). Previous studies showed that VIP-deficient mice exhibit reduced IGF-1 levels 
(Asnicar et al., 2002 and Niewiadomski et al., 2008), and perturbation in the GH/IGF-1 axis is 
associated with dwarfism and increased adiposity in rodents and humans (Lichanska and 
Waters, 2008). We thus hypothesized that the GH/IGF-1 axis is perturbed in Npy6r−/− mice 
and that this contributes to the development of reduced lean mass and late-onset obesity. 
Indeed, Npy6r−/− mice showed significantly reduced serum IGF-1 levels (Figure 7D), 
coinciding with a reduction in hypothalamic expression of growth hormone releasing hormone 
(Ghrh) ( Figure 7E). Additionally, loss of Npy6r in mice led to blunted diurnal variations in 
serum corticosterone levels ( Figure 7F). Importantly, the damped corticosterone rhythm seen 
in Npy6r−/− mice is not due to impaired secretion, since a 24 hr fast elicited comparable 
increases in corticosterone levels in mice of both genotypes, although Npy6r−/− mice showed 
significantly reduced corticosterone levels compared to WT controls under both fed and 
fasted conditions (Figure 7G). Since timing of food intake is linked to corticosterone secretion 
(Sheward et al., 2007) and has been shown to be abrogated in mice with disrupted VIP 
signaling (Bechtold et al., 2008), we investigated food consumption during light and dark 
phases and found significantly reduced daytime feeding in Npy6r−/− mice (Figures 7H and 7I). 
Hence, our data provide evidence that the reduced lean mass and late-onset or diet-induced 
increases in adiposity in mice lacking Npy6r may result from reduced hypothalamic Ghrh 
expression and circulating IGF-1 levels, potentially attributable to impairment in VIP signaling 
in the SCN. 
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Finally, to demonstrate that alterations in downstream VIP
signaling are linked to the observed changes in energy homeo-
stasis such as the reduction of IGF-1 levels, we delivered
VIP(6-28), a VPAC receptors antagonist, via the i.c.v. route to
WT andNpy6r!/!mice, followed 5min later by i.p. administration
of PP. Analysis of serum samples collected 30 min following PP
injection revealed that blockade of VPAC receptors in WT mice
completely prevented the PP-induced increase in serum IGF-1
in WT mice (Figure 7L). Furthermore, the effect of PP to raise
serum IGF-1 was totally absent in Npy6r!/! mice (Figure 7L),
clearly demonstrating involvement of Npy6r signaling via VIP in
controlling the growth hormone axis.
DISCUSSION
In this study, we demonstrate that Npy6r signaling in the SCN is
critical in the regulation of energy homeostasis. Our results show
that body weight, body composition, metabolic rate, and activity
of the hypothalamo-pituitary-somatotrophic axis are signifi-
cantly influenced by Npy6r signaling in mice, since lack of
Npy6r leads to reduced lean mass and increased energy expen-
diture that are accompanied by significant improvements in
glucose homeostasis and reduced hypothalamic Ghrh mRNA
expression and circulating IGF-1 levels. Interestingly, Npy6r-
deficient mice develop late-onset obesity, and this is further
exacerbated when mice are fed a high-fat diet. Additionally, we
demonstrate that PP is an endogenous high-affinity ligand for
Npy6r in mice, since exogenous administration of PP, but not
PYY or PYY3-36, activated Npy6r-expressing neurons in the
SCN, and this effect was absent in Npy6r-deficient mice. The
mechanism by which Npy6r mediates its effects on the GH
axis and energy homeostasis is most likely through alterations
in VIP signaling in the hypothalamus. This is demonstrated by
the strong overlap in expression of Vip and Npy6r within the
SCN, the brain region to which the Npy6r is confined, and
the significant reduction in Vip expression in this nucleus in the
absence of Npy6r signaling. Moreover, the fact that i.p. PP injec-
tion increases energy expenditure and decreases food intake,
hypothalamic Ghrh mRNA expression, and circulating IGF-1
levels in WT but not in Npy6r!/! mice, and that the effect on
IGF-1 is blocked by prior administration of a VPAC receptors
antagonist, strongly supports this stand.
It has been documented that the SCN contains the master
circadian clock in mammals; it generates distinct temporal
changes in biological processes such as core body temperature
and hormone secretion (Huang et al., 2011). Disruptions in circa-
dian rhythm, whether by genetic or environmental influences,
can result in metabolic dysfunction (Huang et al., 2011). For
instance, mutation of either of two key regulators of the circadian
cycle, circadian locomotor output cycles kaput (CLOCK) or brain
and muscle aryl hydrocarbon receptor nuclear translocator
(ARNT)-like 1 (BMAL1), not only disrupt normal circadian rhythm,
manifesting in loss of normal daily hormonal and feeding pat-
terns, but also predispose mice to metabolic diseases (Mar-
cheva et al., 2010; Rudic et al., 2004; Turek et al., 2005). VIP is
a critical regulator of circadian rhythm in the SCN, with deletion
of VIP or its receptor, VPAC2, leading to loss of circadian rhyth-
micity and synchrony in SCN neurons (Aton et al., 2005; Hannibal
et al., 2011; Harmar et al., 2004). Since our studies demonstrate
that hypothalamic VIP expression is reduced in Npy6r-deficient
mice, it is possible that the impaired circadian rhythm observed
in our Npy6r!/!mice, as evidenced by blunted daily fluctuations
in serum corticosterone levels and reduced light-phase feeding,
may be due to impaired VIP signaling, and therefore could
contribute to the development of metabolic abnormalities in
these mice.
In addition to regulating circadian rhythm, VIP is an important
regulator of the GH axis. VIP is known to stimulate GH release in
rats in vivo (Bluet-Pajot et al., 1987), in cultured bovine adenohy-
pophysial cells (Soliman et al., 1995), and in perifused bovine
adenohypophysis (Hashizume and Kanematsu, 1990). More-
over, loss of VIP or VPAC2 in mice leads to reduced growth in
association with reduced circulating IGF-1 levels (Asnicar
et al., 2002; Niewiadomski et al., 2008). Indeed, we demonstrate
that blockade of VPAC abolishes the Npy6r-mediated alteration
of circulating IGF-1 levels. This finding, combined with our
observations of reduced SCN Vip mRNA expression and
reduced GH/IGF-1 axis activity in our Npy6r!/! mice, suggests
that the reduced lean mass and late onset obesity observed in
the absence of Npy6r signaling are due to perturbations in
normal VIP regulation of the GH/IGF-1 axis. Consistent with
known effects of reduced circulating IGF-1 levels in inducing
obesity (Rosen et al., 2004), our data suggest that the lower
circulating IGF-1 levels could account for the decreased lean
mass and the increased relative adiposity in Npy6r!/! mice.
Thus, impairment in function of the GH/IGF-1 axis, as well as
impaired circadian rhythmicity resulting from defects in VIP
neuronal signaling pathways in the SCN, could have contributed
to the reduction in lean body mass and the development of late-
onset obesity in Npy6r!/! mice.
In this study, PP was found to be the only high-affinity ligand
that can trigger significant elevation of Fos expression in the
SCN in WT compared to Npy6r!/! mice. PP is released from
pancreatic F cells in response to stimuli such as food intake
and hypoglycemia, mainly by vagal muscarinic activation (Havel
et al., 1993). Previously it was thought to be a ligand only for the
Ppyr1, triggering responses in the brain stem and ARC to inhibit
food intake (Lin et al., 2009) and enhance digestive events such
as gastric secretion, motility, and emptying by subsequent acti-
vation of vagal cholinergic pathways (McTigue et al., 1997). Lack
Figure 7. Pancreatic Polypeptide-Mediated Npy6r Signaling Controls VIP Expression in the SCN
(A–C) (A) Vip mRNA expression in the hypothalamus and (B and C) in SCN of Npy6r!/! mice and WT controls.
(D and E) Fasted serum IGF-1 and hypothalamic Ghrh mRNA expression were determined in chow-fed Npy6r!/! and WT mice.
(F and G) Serum corticosterone levels were assessed at intervals of 6 hr or under fasted condition in Npy6r!/! mice and WT controls.
(H and I) Light- and dark-phase food intake was measured for 6 consecutive days in 16- and 23-week-old Npy6r!/! and WT mice.
(J and K) Npy6r!/! and WT mice were injected with either saline or PP, and Ghrh mRNA levels in ARC were assessed.
(L) Npy6r!/! and WT mice were injected with either saline, PP, or PP and VIP receptor antagonist. Subsequently, serum IGF-1 levels were determined by using
IGF-1 ELISA kit. Data are means ±SEM of four to eight mice per group. See also Figure S7.
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 Further evidence supporting the notion of a PP-controlled GH/IGF-1 axis comes from 
experiments in which we injected PP via the i.c.v. route and measured the consequences on 
Ghrh mRNA expression in WT compared to Npy6r−/− mice. While i.c.v. administration of PP to 
WT mice led to a significant increase in Ghrh mRNA levels in the ARC, this PP-dependent 
effect was absent in Npy6r−/− mice (Figures 7J and 7K). Together with our findings of SCN-
specific Npy6r expression, colocalization of Npy6r with VIP in the SCN, reduced expression of 
Vip mRNA in the SCN of Npy6r−/− mice, and PP-induced Fos activation in the SCN, these 
data indicate that alterations in GH/IGF-1 axis activity in Npy6r−/− mice are a direct 
consequence of the lack of PP-induced activation of Npy6r in the SCN, possibly via VIP. 
 Finally, to demonstrate that alterations in downstream VIP signaling are linked to the 
observed changes in energy homeostasis such as the reduction of IGF-1 levels, we delivered 
VIP(6-28), a VPAC receptors antagonist, via the i.c.v. route to WT and Npy6r−/− mice, 
followed 5 min later by i.p. administration of PP. Analysis of serum samples collected 30 min 
following PP injection revealed that blockade of VPAC receptors in WT mice completely 
prevented the PP-induced increase in serum IGF-1 in WT mice (Figure 7L). Furthermore, the 
effect of PP to raise serum IGF-1 was totally absent in Npy6r−/− mice (Figure 7L), clearly 
demonstrating involvement of Npy6r signaling via VIP in controlling the growth hormone axis. 
 
Discussion 
 
In this study, we demonstrate that Npy6r signaling in the SCN is critical in the regulation of 
energy homeostasis. Our results show that body weight, body composition, metabolic rate, 
and activity of the hypothalamo-pituitary-somatotrophic axis are significantly influenced by 
Npy6r signaling in mice, since lack of Npy6r leads to reduced lean mass and increased 
energy expenditure that are accompanied by significant improvements in glucose 
homeostasis and reduced hypothalamic Ghrh mRNA expression and circulating IGF-1 levels. 
Interestingly, Npy6r-deficient mice develop late-onset obesity, and this is further exacerbated 
when mice are fed a high-fat diet. Additionally, we demonstrate that PP is an endogenous 
high-affinity ligand for Npy6r in mice, since exogenous administration of PP, but not PYY or 
PYY3-36, activated Npy6r-expressing neurons in the SCN, and this effect was absent in 
Npy6r-deficient mice. The mechanism by which Npy6r mediates its effects on the GH axis 
and energy homeostasis is most likely through alterations in VIP signaling in the 
hypothalamus. This is demonstrated by the strong overlap in expression of Vip and Npy6r 
within the SCN, the brain region to which the Npy6r is confined, and the significant reduction 
in Vip expression in this nucleus in the absence of Npy6r signaling. Moreover, the fact that i.p. 
PP injection increases energy expenditure and decreases food intake, hypothalamic Ghrh 
mRNA expression, and circulating IGF-1 levels in WT but not in Npy6r−/− mice, and that the 
effect on IGF-1 is blocked by prior administration of a VPAC receptors antagonist, strongly 
supports this stand. 
 It has been documented that the SCN contains the master circadian clock in 
mammals; it generates distinct temporal changes in biological processes such as core body 
temperature and hormone secretion (Huang et al., 2011). Disruptions in circadian rhythm, 
whether by genetic or environmental influences, can result in metabolic dysfunction (Huang 
et al., 2011). For instance, mutation of either of two key regulators of the circadian cycle, 
circadian locomotor output cycles kaput (CLOCK) or brain and muscle aryl hydrocarbon 
receptor nuclear translocator (ARNT)-like 1 (BMAL1), not only disrupt normal circadian 
rhythm, manifesting in loss of normal daily hormonal and feeding patterns, but also 
predispose mice to metabolic diseases (Marcheva et al., 2010, Rudic et al., 2004 and Turek 
et al., 2005). VIP is a critical regulator of circadian rhythm in the SCN, with deletion of VIP or 
its receptor, VPAC2, leading to loss of circadian rhythmicity and synchrony in SCN neurons 
(Aton et al., 2005, Hannibal et al., 2011 and Harmar et al., 2004). Since our studies 
demonstrate that hypothalamic VIP expression is reduced in Npy6r-deficient mice, it is 
possible that the impaired circadian rhythm observed in our Npy6r−/− mice, as evidenced by 
blunted daily fluctuations in serum corticosterone levels and reduced light-phase feeding, may 
be due to impaired VIP signaling, and therefore could contribute to the development of 
metabolic abnormalities in these mice. 
 In addition to regulating circadian rhythm, VIP is an important regulator of the GH 
axis. VIP is known to stimulate GH release in rats in vivo (Bluet-Pajot et al., 1987), in cultured 
bovine adenohypophysial cells (Soliman et al., 1995), and in perifused bovine 
adenohypophysis (Hashizume and Kanematsu, 1990). Moreover, loss of VIP or VPAC2 in 
Yulayaningsih	  et	  al.:	  Cell	  Metabolism,	  19(1):	  58-­‐72,	  2012	  	  
mice leads to reduced growth in association with reduced circulating IGF-1 levels (Asnicar 
et al., 2002 and Niewiadomski et al., 2008). Indeed, we demonstrate that blockade of VPAC 
abolishes the Npy6r-mediated alteration of circulating IGF-1 levels. This finding, combined 
with our observations of reduced SCN Vip mRNA expression and reduced GH/IGF-1 axis 
activity in our Npy6r−/− mice, suggests that the reduced lean mass and late onset obesity 
observed in the absence of Npy6r signaling are due to perturbations in normal VIP regulation 
of the GH/IGF-1 axis. Consistent with known effects of reduced circulating IGF-1 levels in 
inducing obesity ( Rosen et al., 2004), our data suggest that the lower circulating IGF-1 levels 
could account for the decreased lean mass and the increased relative adiposity in Npy6r−/− 
mice. Thus, impairment in function of the GH/IGF-1 axis, as well as impaired circadian 
rhythmicity resulting from defects in VIP neuronal signaling pathways in the SCN, could have 
contributed to the reduction in lean body mass and the development of late-onset obesity in 
Npy6r−/− mice. 
 In this study, PP was found to be the only high-affinity ligand that can trigger 
significant elevation of Fos expression in the SCN in WT compared to Npy6r−/− mice. PP is 
released from pancreatic F cells in response to stimuli such as food intake and hypoglycemia, 
mainly by vagal muscarinic activation (Havel et al., 1993). Previously it was thought to be a 
ligand only for the Ppyr1, triggering responses in the brain stem and ARC to inhibit food 
intake ( Lin et al., 2009) and enhance digestive events such as gastric secretion, motility, and 
emptying by subsequent activation of vagal cholinergic pathways (McTigue et al., 1997). Lack 
of Ppyr1 signaling in mice leads to reduced body weight and fat mass on a lean background, 
and attenuation of certain aspects of the obesity syndrome and enhanced fertility on a 
background of leptin deficiency ( Sainsbury et al., 2002b and Zhang et al., 2010). However, 
satiety regulation of PP via Ppyr1 signaling seems to be mainly confined to the ARC in the 
hypothalamus, particularly to neurons that coexpress alpha melanocyte stimulating hormone 
(α-MSH) ( Lin et al., 2009). It is possible that the reduced body weight or attenuated obesity 
syndrome of Ppyr1−/− mice was mediated by the high circulating PP concentrations seen in 
these mice, acting on other Y receptors besides Ppyr1, such as the herein-identified Npy6r. In 
support of this, PP transgenic mice, which have a 20-fold increase in plasma PP levels, have 
a similar metabolic phenotype to Ppyr1−/− mice (Ueno et al., 1999). Our current data extend 
these findings to suggest that the late-onset obesity phenotype of our Npy6r−/− mice could be 
mediated by lack of action of PP on Npy6r in the SCN. 
 In summary, our study demonstrates that Npy6r is a critical regulator of energy 
homeostasis and body composition, with germline deletion of Npy6r leading to reduced body 
weight, inhibition of lean body mass, and an age-dependent increase in adiposity that is 
exacerbated by high-fat feeding, with these effects likely mediated via the lack of Npy6r 
signaling in the SCN to influence the VIP-GH/IGF-1 axis. Future studies in mice into the 
function and possible clinical utility of Y receptors and their ligands as drug targets must 
therefore take into account this new knowledge that Npy6r plays an important role in the 
regulation of energy homeostasis. 
 
Experimental Procedures 
 
Animals 
All animal care and experiments were approved by the Garvan/St. Vincent’s Animal Ethics 
Committee. Npy6r−/− mice were generated and genotyped as described in Supplemental 
Experimental Procedures. Male mice on a mixed C57BL/6–129SvJ background were used for 
all experiments, except where noted. Mice were housed under a controlled temperature of 
22°C and a 12 hr light cycle (lights on from 07:00 to 19:00 hr) with ad libitum access to water 
and a standard chow diet (6% calories from fat, 21% calories from protein, 71% calories from 
carbohydrate, 2.6 kcal/g, Gordon’s Specialty Stock Feeds, Australia) or fed a HFD (43% 
kilojoules from fat, 17% kilojoules from protein, 40% kilojoules from carbohydrate, 4.8 kcal/g, 
Specialty Feeds, Australia) for 16 weeks starting from 7–8 weeks of age. 
 
RNA Extraction and Quantitative Real-Time PCR 
Hypothalami were dissected and immediately frozen in liquid N2, and RNA was extracted 
using Trizol Reagent (Sigma, St. Louis, MO) and processed for quantitative real-time PCR 
with the Light-Cycler 480 Real-Time PCR system (Roche, Switzerland) as described in the 
Supplemental Experimental Procedures. 
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Metabolic Measurements and Body Composition 
Weekly body weight was determined from 6 weeks of age onward, unless otherwise stated. 
Food intake and fecal output were examined in chow- and high-fat-fed mice under normal and 
fasting states as described in the Supplemental Experimental Procedures. Whole-body lean 
and fat masses were determined by DXA (Lunar Piximus II mouse densitometer; GE 
Healthcare, UK) as previously described (Baldock et al., 2009 and Zhang et al., 2010). VO2, 
energy expenditure, RER, and physical activity were assessed using an indirect calorimeter 
(Oxymax series; Columbus Instruments, Columbus, OH) as described in the Supplemental 
Experimental Procedures. 
 
Glucose Tolerance Tests and Serum Assays 
Mice were fasted for 16–18 hr and i.p. administered with glucose (1 mg/kg body weight). 
Blood glucose levels were assessed at 0, 15, 30, 60, and 90 min after glucose administration 
using an Accu-chek Go glucometer (Roche, Dee Why, Australia). Serum was collected and 
stored for subsequent insulin assay. Serum insulin, testosterone, IGF-1, VIP, and 
corticosterone levels were measured in accordance with the manufacturers’ specifications as 
described in the Supplemental Experimental Procedures. 
 
Oil Red O and β-Galactosidase Staining 
Frozen livers sections (6 µm) were cut on a cryostat, mounted on slides, and processed for oil 
red O staining as described in the Supplemental Experimental Procedures. Coronal brain and 
peripheral tissue frozen sections (25 µm) were mounted on slides and processed for β-
galactosidase histochemistry as described in the Supplemental Experimental Procedures. 
 
Immunohistochemistry 
Animals were anesthetized, and the brains were perfused with saline and then 4% 
paraformaldehyde (PFA). Brains were postfixed in 4% PFA, then placed in 30% sucrose 
overnight and cut at 35 µm on a cryostat. Subsequently, immunohistochemistry was 
performed using antibodies against Fos, p-ERK, VIP, or AVP. Fos expression was visualized 
in brain sections containing the SCN (Bregma −0.34 mm through to −0.70 mm) (Franklin and 
Paxinos, 1997) with a light microscope (Leica, Heerbrugg, Switzerland). The number of Fos-
positive neurons within a constant and defined frame was counted using ImageJ64 software 
(National Institutes of Health). 
 
In Situ Hybridization and Colocalization Study 
Coronal brain sections (30 µm) were cut on a cryostat and mounted on slides. Matching 
sections from the same coronal brain level from different groups of mice were examined 
together using radiolabeled DNA oligonucleotides complementary to mouse Vip and Ghrh. 
Sequence of probes and details of the in situ hydridization methodology can be found in the 
Supplemental Experimental Procedures. For colocalization of Npy6r and Vip study, coronal 
brain section were first processed for β-gal staining, then followed by in situ hydridization as 
described in the Supplemental Experimental Procedures. Slides were visualized and imaged 
with a light microscope (Leica, Heerbrugg, Switzerland). 
 
Stereotaxic Brain Delivery of Peptides 
Adult mice were anaesthetized and placed on a Kopf stereotaxic frame (David Kopf 
Instruments, Tujunga, CA, USA). A total of 1 µl PP or 1.5 µl VPAC2 antagonist (2 µg/ul) was 
injected into the lateral ventricle at a rate of 0.1 µL/min using a 10 µl Hamilton syringe 
attached to Micro4 Micro Syringe Pump Controller (World Precision Instruments Inc., 
Sarasota). The injection coordinates were (from bregma) as follows: anteroposterior, –
0.34 mm; mediolateral, ±1.00 mm; and dorsoventral, –2.5 mm (Franklin and Paxinos, 1997). 
Animals were kept on a heating pad during surgery. 
 
Statistical Analyses 
All data are expressed as mean ±SEM. A two-tailed Student’s t test was used to test the 
difference between two groups of mice. Differences among groups of mice were assessed by 
two-way ANOVA or repeated-measures ANOVA. Bonferroni post hoc tests were performed to 
identify differences among means. Statistical analyses were assessed using Prism software 
(GraphPad Software, Inc, LaJolla). Differences were regarded as statistically significant if p < 
0.05. 
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